Abstract: It has been found that Spi-B, in cooperation with IRF-7, induces type I IFN production. This invention is based on the finding, and provides a type I IFN production inhibitor comprising an antisense nucleic acid or siRNA against Spi-B, or an expression vector capable of expressing the same; a screening method for a substance capable of inhibiting type I IFN production, comprising selecting a substance that suppresses the expression or function of Spi-B as a substance capable of inhibiting type I IFN production; and a type I IFN production inducer comprising an expression vector capable of expressing Spi-B and an expression vector capable of expressing IRF-7 in combination, and the like.

Abstract: The present invention provides an agent for treating wound, containing a substance that suppresses the expression or function of PDLIM2. The substance that suppresses the expression or function of PDLIM2 is preferably an siRNA or antisense nucleic acid capable of specifically suppressing the expression of PDLIM2, or an expression vector capable of expressing said polynucleotide. In addition, the present invention provides a method of screening for a substance capable of treating wounds, including determining whether or not a test substance is capable of suppressing the expression or function of PDLIM2.

Abstract: The present invention provides an agent for treating wound, containing a substance that suppresses the expression or function of PDLIM2. The substance that suppresses the expression or function of PDLIM2 is preferably an siRNA or antisense nucleic acid capable of specifically suppressing the expression of PDLIM2, or an expression vector capable of expressing said polynucleotide. In addition, the present invention provides a method of screening for a substance capable of treating wounds, including determining whether or not a test substance is capable of suppressing the expression or function of PDLIM2.

Abstract: An object of the present invention is to elucidate the role of IKK? in TLR signaling and provide an agent and a method for controlling interferon-?. The present invention provides an agent for suppressing interferon-? production which comprises an agent for inhibiting IKK?.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability, and a novel membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability or a part of it. A method for producing said novel membrane protein polypeptide by preparing transformants by transforming a host cell with a vector containing said gene and culturing said transformants. A monoclonal antibody recognizing said novel membrane protein polypeptide. The above gene encodes the membrane protein having pre-B cell growth-supporting ability. The homogeneous and purified novel membrane protein polypeptide can be produced in large quantities and in addition, monoclonal antibodies recognizing said polypeptide can be produced; thus it becomes possible to identify rheumatoid arthritis (RA) and also prepare reagents for the clinical diagnosis thereof.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability and a membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability. This gene encodes the membrane protein having pre-B cell growth-supporting ability. A method for producing a membrane protein having pre-B cell growth-supporting ability by transforming a host cell with a vector containing a gene encoding it and culturing the resulting transformants. A monoclonal antibody recognizing this membrane protein. The homogeneous and purified novel membrane protein pelypeptide can be produced in large quantities and used to produce monoclonal antibodies useful for identifying rheumatoid arthritis (RA) and for the preparation of reagents for the clinical diagnosis thereof.

Abstract: The present invention provides a monoclonal antibody which binds to a polypeptide as set forth in SEQ ID NO: 1 as described herein.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability, and a novel membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability or a part of it. A method for producing said novel membrane protein polypeptide by preparing transformants by transforming a host cell with a vector containing said gene and culturing said transformants. A monoclonal antibody recognizing said novel membrane protein polypeptide. The above gene encodes the membrane protein having pre-B cell growth-supporting ability. The homogeneous and purified novel membrane protein polypeptide can be produced in large quantities and in addition, monoclonal antibodies recognizing said polypeptide can be produced; thus it becomes possible to identify rheumatoid arthritis (RA) and also prepare reagents for the clinical diagnosis thereof.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability, and a novel membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability or a part of it. A method for producing said novel membrane protein polypeptide by preparing transformants by transforming a host cell with a vector containing said gene and culturing said transformants. A monoclonal antibody recognizing said novel membrane protein polypeptide.

Abstract: This invention relates to a gene encoding a polypeptide having pre-B cell growth-supporting ability, and an adhesion molecule of the polypeptide consisting of 318 amino acid residues having pre-B cell growth-supporting ability, or a part of it. Said adhesion molecule is produced by preparing transformants such as microorganism or cells by transforming a host cell with a vector containing said gene and culturing said transformants.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability, and a novel membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability or a part of it. A method for producing said novel membrane protein polypeptide by preparing transformants by transforming a host cell with a vector containing said gene and culturing said transformants. A monoclonal antibody recognizing said novel membrane protein polypeptide.

Abstract: The present invention provides (1) a polypeptide containing amino acids 1 to 269 of the amino acid sequence shown in SEQ ID No: 1, (2) polypeptide containing amino acids 1 to 290 of the amino acid sequence shown in SEQ ID No. 1, (3) a polypeptide containing amino acids −28 to 269 of the amino acid sequence shown in SEQ ID No. 1, and (4) a polypeptide containing amino acids −28 to 290 of the amino acid sequence shown in SEQ ID No. 1. The present invention also provides a fusion protein in which residues 1 to 269 of SEQ ID No. 1 are linked to a second polypeptide and a fusion protein in which residues 1 to 290 of SEQ ID No. 1 are linked to a second polypeptide.

Abstract: Isolated DNAs which encode polypeptides having pre-B cell growth-supporting ability.

Abstract: A gene encoding a novel membrane protein polypeptide having pre-B cell growth-supporting ability, and a novel membrane protein polypeptide consisting of 180 amino acid residues having pre-B cell growth-supporting ability, or a part of it. A method for producing the novel membrane protein polypeptide by preparing transformants by transforming a host cell with a vector containing the gene and culturing the transformants. The homogenous and purified novel membrane protein polypeptide can be produced in large quantities and in addition, monoclonal antibodies recognizing said polypeptide can be produced; thus it becomes possible to identify rheumatoid arthritis (RA) and also prepare reagents for the clinical diagnosis thereof.

Abstract: This invention relates to a gene encoding a polypeptide having pre-B cell growth-supporting ability, and an adhesion molecule of the polypeptide consisting of 318 amino acid residues having pre-B cell growth-supporting ability, or a part of it. Said adhesion molecule is produced by preparing transformants such as microorganism or cells by transforming a host cell with a vector containing said gene and culturing said transformants.The above gene encodes the novel adhesion molecule enhancing the pre-B cell growth-supporting ability on the bone marrow cell and the synovial cell derived from patients with rheumatoid arthritis (RA) and multiple myeloma (MM). The homogeneous and purified adhesion molecule having pre-B cell growth-supporting ability can be produced in large quantities, and therefore it is possible to identify multiple myeloma (MM) and rheumatoid arthritis (RA), and also prepare reagents for the clinical diagnosis thereof.